NK cell therapy-Pipeline Insight, 2021 | Analytical Research Cognizance

NK cell therapy-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667940
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “NK cell therapy - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in NK cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
NK cell therapy Understanding

NK cell therapy: Overview
Natural Killer (NK) Cells are recognized for their ability to kill cancerous cells. These are lymphocytes hailing from the same family as that of T and B cells, however, NK cells are classified as group I Innate Lymphocytes (ILCs) and respond quickly to a wide variety of conditions including cancer.

Function –Natural killer (NK) cells are granular lymphocytes that play important roles in immunity against viruses and in the immune surveillance of tumors. In addition to being a potent innate source of IFN-γ, NK cells hold cytoplasmic granula that contain perforin and granzymes involved in cell-mediated cytotoxicity.
NK cell therapy: NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells.

NK cell therapy Emerging Drugs Chapters
This segment of the NK cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NK cell therapy Emerging Drugs
haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest
NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio’s IL-15 superagonist for the treatment of advanced refractory metastatic merkel cell carcinoma. The therapy leverages the company’s hANK Cell Platform. The drug is in Phase II of clinical development.
Further product details are provided in the report……..

NK cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different NK cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on NK cell therapy
There are approx. 15+ key companies which are developing the NK cell therapy. The companies which have their NK cell therapy drug candidates in the most advanced stage, i.e. phase II include, Nantkwest.

Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
NK cell therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NK cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK cell therapy drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence NK cell therapy R&D. The therapies under development are focused on novel approaches for NK cell therapy.
A global increase in Cancer incident cases and relapses has led to an inclination towards Novel effective treatments such as adjuvant therapy drugs, and NK cell therapies.


NK cell therapy Report Insights
NK cell therapy Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

NK cell therapy Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing NK cell therapy drugs?
How many NK cell therapy drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for NK cell therapy?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NK cell therapy therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for NK cell therapy and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Nantkwest
Coronado Biosciences
Artiva Biotherapeutics
Affimed
Bristol-Myers Squibb
Celularity Incorporated
ZIOPHARM Oncology
Surface Oncology
Sorrento Therapeutics
AvidBiotic Corporation

Key Products
Avelumab; N-803; hank
AB-101
CNDO-109-AANK Cells
NK cells combined with the antibody AFM13 (AFM13-NK) and AFM13 alone
Lirilumab; Nivolumab; Ipilimumab
CYNK-001

Introduction
Executive Summary
NK cell therapy: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NK cell therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NK cell therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NK cell therapy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Avelumab; N-803; haNK: NantKwest
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CNDO-109-AANK Cells: Coronado Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NK cell therapy Key Companies
NK cell therapy Key Products
NK cell therapy- Unmet Needs
NK cell therapy- Market Drivers and Barriers
NK cell therapy- Future Perspectives and Conclusion
NK cell therapy Analyst Views
NK cell therapy Key Companies
Appendix

Table 1 Total Products for NK cell therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for NK cell therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products